Welcome to our dedicated page for Cosciens Biopharma news (Ticker: CSCIF), a resource for investors and traders seeking the latest updates and insights on Cosciens Biopharma stock.
COSCIENS Biopharma Inc (CSCIF) is a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions. News about COSCIENS often centers on developments related to its lead pharmaceutical diagnostic product Macrilen (macimorelin) and on commercial agreements that extend the product’s reach into new territories.
Macrilen is described as a ghrelin agonist and the first and only FDA and EMA approved oral test for diagnosing Adult Growth Hormone Deficiency (AGHD). Company announcements highlight how COSCIENS, through its wholly owned subsidiary Aeterna Zentaris GmbH, enters into distribution partnerships to commercialize Macrilen. One example is the exclusive distribution agreement with Wuzhou Drug International Trading Limited for Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan, leveraging the Hong Kong and Macao Medicine and Equipment Connect policy for expedited access in the Greater Bay Area.
Investors and observers following COSCIENS-related news can expect updates on pharmaceutical and diagnostic commercialization, regional distribution agreements, and commentary from management and partners on the strategic fit of Macrilen in endocrinology and specialty diagnostics. News may also reference the company’s natural active ingredient business, which uses proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients used in skincare brands worldwide.
For those tracking CSCIF, this news stream provides context on how COSCIENS seeks to expand Macrilen’s presence in international markets and how its life sciences and natural ingredient activities evolve over time. Regularly reviewing COSCIENS news can help readers understand the company’s progress in pharmaceutical diagnostics and its role as a supplier of plant-based active ingredients.
COSCIENS Biopharma (OTCQB: CSCIF) filed a Rule 13e-3 Transaction Statement with the SEC on April 20, 2026 proposing a two-step Share Capital Amendment to reduce U.S. holders of record below 300 and seek suspension of Exchange Act reporting.
The plan consolidates 150 pre-consolidation shares into one, then splits 50-for-1; holders under 150 would receive US$1.60 per pre-consolidation share and be cashed out. The company estimates approximately US$1.9 million in annualized cost savings if SEC Reporting Suspension is allowed. Shareholder approval at the June 2026 meeting is planned.
COSCIENS Biopharma (OTCQB: CSCIF; TSX: CSCI) issued a notice on April 7, 2026 responding to recent unusual market activity. The company said it does not normally comment on market speculation and confirmed it is not aware of any material undisclosed information that would explain the recent trading increase.
COSCIENS Biopharma (OTCQB: CSCIF, TSX: CSCI) reported Q4 and full‑year 2025 results and a corporate update on March 25, 2026. The company ended 2025 with $7.3M cash, Q4 net loss of $2.2M and FY net loss of $10.4M. Revenue for FY 2025 was $7.5M. Management ceased funding its German subsidiaries and filed for insolvency there on March 23, 2026, expecting ~$1.9M annualized cost savings and removal of €11.0M pension liabilities from consolidation. The company plans to propose suspending Exchange Act reporting while remaining a Canadian reporting issuer and listed on the TSX and OTC market.
COSCIENS (FINRA: CSCIF, TSX: CSCI) announced it will cease funding its German subsidiaries Aeterna Zentaris GmbH and Zentaris IVF GmbH, prompting an expected structured insolvency process and anticipated surrender of rights to Macrilen® (macimorelin). The company cited disappointing Phase 3 DETECT results and a Type C FDA meeting as a setback to pediatric expansion plans.
The company said it will significantly reduce operating expenses and refocus on its active ingredients business, while evaluating other strategic options including sales, licenses, and U.S. entry alternatives.
COSCIENS (TSX: CSCI; FINRA: CSCIF) announced that subsidiary Aeterna Zentaris GmbH signed an exclusive 10-year distribution agreement with Wuzhou Drug International for Macrilen (macimorelin) in Hong Kong, Macao, Singapore, and Guangdong and Hainan provinces.
The deal assigns Wuzhou responsibility for registration, importation and commercialization and leverages the "Hong Kong and Macao Medicine and Equipment Connect" policy for expedited access in the Greater Bay Area. The agreement includes a minimum initial order of approximately €800,000.